WESTON, Fla., June 25, 2004 (PRIMEZONE) -- TheSUBWAY.com announces the following stocks to its Stock Market Standouts List: Xechem International Inc. (OTCBB:XKEM), Juniper Networks Inc. (Nasdaq:JNPR), Sepracor Inc. (Nasdaq:SEPR), Tellabs Inc. (Nasdaq:TLAB).
Xechem International Inc. (OTCBB:XKEM) Xechem International, Inc. and Xechem, Inc. filed an antitrust suit against Bristol-Myers Squibb Company in the U.S. District Court seeking treble damages in connection with BMS' alleged engagement in a series of unlawful acts to delay competition in generic versions of paclitaxel. The lawsuit had been initially dismissed by the District Court on the grounds that the statute of limitations barred the action.
On June 23, 2004 the U.S. Court of Appeals for the Seventh Circuit, however, reversed the District Court opinion and determined that the basis for dismissal was improper. Although there has been no determination on the merits of the case, Xechem intends to vigorously pursue its claims against BMS.
Xechem International, Inc. is a fully integrated biopharmaceutical company focusing on phytopharmaceuticals and other proprietary technologies for orphan diseases. Its principal product under development is NICOSAN(TM)/HEMOXIN(TM), which has shown efficacy in the treatment of sickle cell disease.
Other stocks highlighted include Juniper Networks Inc. (Nasdaq:JNPR): Stock Standouts List, Sepracor Inc. (Nasdaq:SEPR): Stock Standouts List, Tellabs Inc. (Nasdaq:TLAB) Stock Standouts List.
TheSUBWAY.com's Daily Stock Updates:
TheSUBWAY.com highlights stocks that are in the news, have traded high volume, or experienced a large change in price in recent sessions. The aforementioned commentary is not meant to be indicative of a "long term" view of any of the companies listed.
ABOUT TheSUBWAY.com:
TheSUBWAY.com, a leader in corporate communications and finance, provides all investors with a wide-ranging set of financial tools, including original stock market commentary, stock quotes, interactive charts, portfolio watch, live chat and message boards, etc., plus the latest news, press releases, investment opinions, and research reports for all companies highlighted on the site. For more daily commentary, go to http://www.thesubway.com/sub_comm.asp.
All material herein was prepared by Capital Research Group, Inc. (CRG) based upon information believed to be reliable. The information contained herein is not guaranteed by CRG to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. CRG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.thesubway.com or mentioned herein. CRG has been compensated by third party shareholders or with cash from the company on behalf of one or more of the companies mentioned in this opinion. (crg has not been compensated but could receive up to one hundred thousand dollars for xkem. Crg has purchased approximately eight hundred thousand shares in the open market) CRG intends to sell its shares. CRG has sold approximately five hundred thousand shares to date. CRG may sell its shares for less than the target price given in this opinion. CRG's affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. CRG will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.